{"id":"W4243385540","doi":"10.1200/jco.2012.30.18_suppl.lba1","title":"Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Trastuzumab emtansine; Lapatinib; Capecitabine; Taxane; Trastuzumab; Metastatic breast cancer; Internal medicine; Interim analysis; Adverse effect; Gastroenterology; Refractory (planetary science); Tolerability; Breast cancer; Oncology; Cancer; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003831368,0.002148993,0.002091636,0.000575636,0.0004916352,0.0009026311,0.001562677,0.001411527,0.01038594],"category_scores_gemma":[0.001953647,0.0006918665,0.001909804,0.0005364822,0.0007964346,0.000663147,0.0004298765,0.003490005,0.001829188],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001125516,"about_ca_system_score_gemma":0.001426856,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008727534,"about_ca_topic_score_gemma":0.002691547,"domain_scores_codex":[0.9991667,0.0005180071,0.00004434663,0.00009004397,0.00006272244,0.00011813],"domain_scores_gemma":[0.9983596,0.0004261249,0.0003803463,0.0001239942,0.0001017474,0.0006081297],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8644921,0.04524702,0.005176455,0.001745939,0.002399228,0.0002761058,0.0001688216,0.002298591,0.0195609,0.0001892749,0.009979621,0.04846607],"study_design_scores_gemma":[0.675148,0.2915781,0.01980693,0.0001153712,0.001970823,0.0003250646,0.00004377684,0.0006358343,0.004492328,0.000106893,0.005747147,0.00002980684],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9409077,0.008539661,0.001879475,0.001252502,0.0003595877,0.01829277,0.01509936,0.0003121144,0.01335683],"genre_scores_gemma":[0.9553478,0.004541977,0.003446575,0.002576885,0.000512219,0.009025063,0.01600347,0.0001151284,0.008430752],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01038594,"threshold_uncertainty_score":0.03474438,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.120029974007668,"score_gpt":0.4837508507159989,"score_spread":0.363720876708331,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}